Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SARS-CoV-2-IN-15 (compound 11) is a niclosamide analogue that contains higher stability in human plasma and liver S9 enzymes assay than niclosamide. It improves bioavailability and half-life when administered orally. SARS-CoV-2-IN-15 is a potent SARS-CoV-2 inhibitor with an IC 50 of 0.49 μM [1].
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
25 mg | 約6-8 週間 | ¥ 349,000 |
50 mg | 約6-8 週間 | ¥ 454,500 |
100 mg | 約6-8 週間 | ¥ 574,000 |
説明 | SARS-CoV-2-IN-15 (compound 11) is a niclosamide analogue that contains higher stability in human plasma and liver S9 enzymes assay than niclosamide. It improves bioavailability and half-life when administered orally. SARS-CoV-2-IN-15 is a potent SARS-CoV-2 inhibitor with an IC 50 of 0.49 μM [1]. |
分子量 | 315.67 |
分子式 | C14H9ClF3NO2 |
CAS No. | 1580-42-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
SARS-CoV-2-IN-15 1580-42-3 Others Inhibitor inhibitor inhibit